Middle East Pharmaceutical to Increase Capital by SAR 350 Million

The CMA noted that the distribution of these shares is intended for shareholders registered with the Securities Depository Center at the close of the second trading period following the company’s extraordinary general assembly meeting. The specific date for this meeting will be determined by the company's board of directors at a later time.

Following the completion of the issuance, Middle East Pharmaceutical Industries Company will be required to comply with all regulatory disclosures and corporate governance requirements mandated by the CMA. The company has confirmed that the increase will be executed through the capitalization of retained earnings and statutory reserves. Existing shareholders are advised to monitor official announcements regarding the record date for the bonus share distribution.